Advances, Challenges, and Limitations in Serum-Proteome-Based Cancer Diagnosis

Otto-von-Guericke-Universität Magdeburg, Magdeburg, Saxony-Anhalt, Germany
Journal of Proteome Research (Impact Factor: 4.25). 02/2006; 5(1):19-25. DOI: 10.1021/pr050271e
Source: PubMed


Recent advances in medicine have dramatically reduced the incidence and mortality of many cardiovascular, infectious, and certain neoplastic diseases; the overall mortality for most malignant solid tumors remains high. The poor prognosis in these cancers is due, in part, to the absence of adequate early screening tests, leading to delays in diagnosis. Three strategies have been applied to fight cancer: analysis of the molecular mechanisms involved in its pathogenesis and progression, improvement of early diagnosis, and the development of novel treatment strategies. There have been major advances in our understanding of cancer biology and pathogenesis and in the development of new (targeted) treatment modalities. However, insufficient progress has been made with respect to improving the methods for the early diagnosis and screening of many cancers. Therefore, cancer is often diagnosed at advanced stages, delaying timely treatment and leading to poor prognosis. Proteome analysis has recently been used for the identification of biomarkers or biomarker patterns that may allow for the early diagnosis of cancer. This tool is of special interest, since it allows for the identification of tumor-derived secretory products in serum or other body fluids. In addition, it may be used to detect reduced levels or loss of proteins in the serum of cancer patients that are present in noncancer individuals. These changes in the serum proteome may result from cancer-specific metabolic or immunological alterations, which are, at least partly, independent of tumor size or mass, thereby facilitating early discovery.

Download full-text


Available from: Christoph Röcken,
  • Source
    • "Clinically, the standard method of identifying precancerous lesions is based on the pathological examinations requiring multi-step procedures and qualified pathologists. To develop more convenient and efficient methods, several carcinogenic biomarkers have been investigated during the past decades [1], [10]–[15]. However, the complicated and labor-intensive procedures render these techniques far away from routine use [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer can be easily treated when found early. A probe capable of detecting cell transformation may increase the success rate of early diagnosis of cancer. In this report we have tested the ability of a fluorescent, quadruplex DNA binding probe, 3,6-bis(1-methyl-4- vinylpyridinium) carbazole diiodide (BMVC), to detect cell transformation in vitro. BMVC was applied to living cells in several different models of cell transformation, and the fluorescence signals of BMVC were measured. The degrees of cell transformation in these models were characterized by alterations in cellular morphological phenotype and subcellular organization. When BMVC probes were applied, the number of BMVC-positive cells increased in accordance with the degree of transformation. BMVC was capable of significantly detecting formation of foci, increased cellular motility, cell proliferation, cell apoptosis, anchorage-independent growth, and increased invasiveness of transformed cells. These results demonstrate the ability of BMVC probes to detect cell transformation and indicate that BMVC is of promise for use as a probe in early cancer detection.
    PLoS ONE 01/2014; 9(1):e86143. DOI:10.1371/journal.pone.0086143 · 3.23 Impact Factor
  • Source
    • "Biomarkers, the candidate proteins present in biological fluids like serum and plasma that can serve as early detection surrogates for diseases, have tremendous impact on diagnostics and therapeutic monitoring [16]. Biomarkers should be easily detectable and measurable across populations and provide useful information such as early detection of disease, identification of high-risk individuals, prediction of recurrence and monitoring drug treatments. "

    PROTEOMICS - CLINICAL APPLICATIONS 10/2011; 5(9-10):559. DOI:10.1002/prca.201190081 · 2.96 Impact Factor
  • Source
    • "Moreover, blood samples may be easily obtained from patients by minimally invasive , safe procedure. The novel calorimetric assays are described that provides a new window through which to view the properties of the human plasma proteome [20] [21] [22]. Current research we investigated the thermal changes of human blood plasma components in breast cancer patients with different tumour size and with or without lymph node metastasis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is the commonest cause of cancer death in women worldwide, and its incidence has been increasing for many years in economically developed countries. Differential scanning calorimetry (DSC) is more and more often applied for oncological purposes, as it could be used as a new method for diagnose and monitoring tumours. In current research liquid plasma components was detected with DSC in breast cancer patients. The study included 19 women with different tumour diameter (0.5–75mm) and with or without regional lymph node metastases (0–10 metastatic lymph node). Preoperatively peripheral blood samples were collected from the patients and from healthy controls, and plasma components were analysed by DSC technique. The diameter of the tumour tissue and the number of metastatic lymph nodes were evaluated on the basis of postoperative histological results. In our preliminary study we observed thermic changes (e.g. Tm, calorimetric enthalpy) in the blood plasma of breast cancer patients, and we have found correlation with tumour size and with the degree of regional lymph node invasion as well. Further studies are needed to clarify these relationships, but our application of the DSC method has provided a potential tool for the early diagnosis and monitoring of breast cancer patients.
    Thermochimica Acta 09/2011; 524(1):88-91. DOI:10.1016/j.tca.2011.06.019 · 2.18 Impact Factor
Show more